Phase 1, Dose Escalation and Dose Expansion Study of AK117, a CD47-targeting Antibody
Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human, Phase 1, multicenter, open label, single arm, integrated 3-part
dose escalation and dose expansion study designed to evaluate the safety, tolerability, PK,
immunogenicity, pharmacodynamics, and preliminary antitumor activity of AK117 administered
intravenously to adult subjects with relapsed/refractory advanced or metastatic solid tumors
or lymphomas.